From the publishers of JADPRO
Myelofibrosis
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge of ruxolitinib discontinuation syndrome
Last Updated: Thursday, December 4, 2025
Loading...
Advertisement
News & Literature Highlights
Clinical Case Reports
A case of myeloproliferative neoplasm-associated glomerulopathy in a patient with myelofibrosis
Biomedicines
Clinical and molecular insights of arterial and venous thrombosis in myeloproliferative diseases-case-based narrative review
Blood Neoplasia
Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis
Thrombosis Research
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib
Tomography
Fat fraction MRI for longitudinal assessment of bone marrow heterogeneity in a mouse model of myelofibrosis
Frontiers in Oncology
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: A case report and literature review
Blood
Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis
European Journal of Haematology
Efficacy of momelotinib in myelofibrosis patients: Results from a multicenter study
European Journal of Haematology
Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine
Transplantation and Cellular Therapy
Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors
Advertisement
Case Studies
Ruxolitinib Discontinuation Syndrome in a Patient with Primary Myelofibrosis
The Management of Myelofibrosis-Related Anemia
Advertisement
Quizzes
Test your knowledge of ruxolitinib discontinuation syndrome
Test your knowledge of myelofibrosis-related anemia